▲ +49.29% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for ALX Oncology in the last 3 months. The average price target is $90.67, with a high forecast of $103.00 and a low forecast of $50.00. The average price target represents a 49.29% upside from the last price of $60.73.
The current consensus among 7 investment analysts is to buy stock in ALX Oncology.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.